Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies

被引:90
|
作者
de Kort, H. [1 ]
Willicombe, M. [2 ]
Brookes, P. [3 ]
Dominy, K. M. [1 ]
Santos-Nunez, E. [3 ]
Galliford, J. W. [2 ]
Chan, K. [2 ]
Taube, D. [2 ]
McLean, A. G. [2 ]
Cook, H. T. [1 ]
Roufosse, C. [1 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England
[2] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Imperial Coll Kidney & Transplant Ctr, London, England
[3] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Histocompatibil & Immunogenet Lab, London, England
关键词
Antibody-mediated rejection; C4d; donor-specific antibodies; histopathology; microcirculation inflammation; renal transplantation; ACUTE HUMORAL REJECTION; HLA ANTIBODIES; KIDNEY-TRANSPLANT; MEDIATED REJECTION; ALLOGRAFT PATHOLOGY; GRAFT FAILURE; RECIPIENTS; CLASSIFICATION; BIOPSIES;
D O I
10.1111/j.1600-6143.2012.04325.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In renal transplant patients with de novo donor-specific antibodies (dnDSA) we studied the value of microcirculation inflammation (MI; defined by the addition of glomerulitis (g) and peritubular capillaritis (ptc) scores) to assess long-term graft survival in a retrospective cohort study. Out of all transplant patients with standard immunological risk (n = 638), 79 (12.4%) developed dnDSA and 58/79 (73%) had an indication biopsy at or after dnDSA development. Based on the MI score on that indication biopsy patients were categorized, MI0 (n = 26), MI1?+?2 (n = 21) and MI?=?3 (n = 11). The MI groups did not differ significantly pretransplantation, whereas posttransplantation higher MI scores developed more anti-HLA class I?+?II DSA (p?= 0.011), showed more TCMR (p?<?0.001) and showed a trend to C4d-positive staining (p = 0.059). Four-year graft survival estimates from time of indication biopsy were MI0 96.1%, MI1?+?2 76.1% and MI?=?3 17.1%; resulting in a 24-fold increased risk of graft failure in the MI?=?3 compared to the MI0 group (p = 0.003; 95% CI [3.0196.0]). When adjusted for C4d, MI?=?3 still had a 21-fold increased risk of graft failure (p = 0.005; 95% CI [2.5180.0]), while C4d positivity on indication biopsy lost significance. In renal transplant patients with de novo DSA, microcirculation inflammation, defined by g?+?ptc, associates with graft survival.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [21] Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience
    Christoph B. Waldecker
    Panagiota Zgoura
    Felix S. Seibert
    Sabina Gall
    Peter Schenker
    Frederic Bauer
    Benjamin Rohn
    Richard Viebahn
    Nina Babel
    Timm H. Westhoff
    Journal of Nephrology, 2021, 34 : 2017 - 2026
  • [22] Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific Antibodies Are Due to Acute Rejection Episodes
    Cooper, James E.
    Gralla, Jane
    Cagle, Linda
    Goldberg, Ryan
    Chan, Laurence
    Wiseman, Alexander C.
    TRANSPLANTATION, 2011, 91 (10) : 1103 - 1109
  • [23] Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation
    Bamoulid, Jamal
    Roodenburg, Afaf
    Staeck, Oliver
    Wu, Kaiyin
    Rudolph, Birgit
    Brakemeier, Susanne
    Halleck, Fabian
    Lehner, Lukas
    Schoenemann, Constanze
    Lachmann, Nils
    Budde, Klemens
    TRANSPLANTATION, 2017, 101 (09) : 2165 - 2174
  • [24] The impact of early de novo donor-specific antibodies on lung transplant outcomes: Is timing everything?
    King, Christopher S.
    Cochrane, Adam B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (09) : 1057 - 1058
  • [25] Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients
    Razia, Deepika
    Hu, Chengcheng
    Cherrier, Lauren
    Nasar, Aasya
    Walia, Rajat
    Tokman, Sofya
    TRANSPLANT IMMUNOLOGY, 2022, 75
  • [26] The meaning of donor-specific antibodies after heart transplant
    Barten, Markus J.
    Zuckermann, Andreas
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2019, 24 (03) : 252 - 258
  • [27] Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy
    Messina, Maria
    Ariaudo, Claudia
    Barbato, Loredana Pratico
    Beltramo, Silvia
    Mazzucco, Gianna
    Amoroso, Antonio
    Ranghino, Andrea
    Cantaluppi, Vincenzo
    Fop, Fabrizio
    Segoloni, Giuseppe Paolo
    Biancone, Luigi
    TRANSPLANT IMMUNOLOGY, 2015, 33 (01) : 7 - 12
  • [28] Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation
    Wiebe, Chris
    Nickerson, Peter
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2013, 18 (04) : 470 - 477
  • [29] Peritubular Capillary Basement Membrane Multilayering in Renal Allograft Biopsies of Patients With De Novo Donor-Specific Antibodies
    de Kort, Hanneke
    Willicombe, Michelle
    Brookes, Paul
    Moran, Linda B.
    Santos-Nunez, Eva
    Galliford, Jack W.
    Taube, David
    McLean, Adam G.
    Moss, Jill
    Cook, H. Terence
    Roufosse, Candice
    TRANSPLANTATION, 2016, 100 (04) : 889 - 897
  • [30] Development of de novo donor-specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction
    Hod-Dvorai, Reut
    Lee, Ryan
    Muluhngwi, Penn
    Raijmakers, Mariella
    Shetty, Aneesha
    Tambur, Anat R.
    Ison, Michael G.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (01)